Raji rituximab
TīmeklisIn addition, rituximab enhanced the cell growth inhibition and apoptotic cell death induced by the oxidative agent, H(2)O(2). We propose that rituximab mediates a … Tīmeklis2016. gada 1. jūl. · Rituximab is a CD20-specific monoclonal antibody that induces CDC and ADCC of B cells, including the B cell lines Ramos and Raji (Bornstein et al., 2009). Ramos and Raji target cells were labeled with calcein AM and incubated with complement containing rabbit serum to a final concentration of 10% and rituximab …
Raji rituximab
Did you know?
Tīmeklis2024. gada 6. febr. · In our previous study, rituximab was conjugated onto the surface of DOX - loaded microbubbles to improve targetability to CD20 receptor-overexpressed Raji cells, and rituximab conjugated and DOX-loaded microbubbles combined with ultrasound increased the release of DOX, resulting in enhanced antitumor efficacy . TīmeklisThe anti-human SIRPα Ab also markedly enhanced the inhibitory effect of rituximab on the growth of tumors formed by Raji cells in hSIRPα-DKO mice. Our results thus suggest that the combination of Abs to human SIRPα with therapeutic Abs specific for tumor antigens warrants further investigation for potential application to cancer …
TīmeklisRituximab-blended samples containing mixtures of fully deglyco-sylated and fully N-glycosylated antibody were assayed in the ADCC Reporter Bioassay against a 100% relative activity reference sample of fully N-glycosylated rituximab in the same plate. Target cells were ADCC Bioassay Target Cells (WIL2-S), and the E:T ratio was 6:1. Tīmeklis2015. gada 13. jūl. · After coculturing with Rituximab, both Ramos and Raji B cells evolved to become Rituximab resistant with low CD20 expression on the cell surface (Fig. 2C). As a result, the nonmodified Rituximab dramatically lost its activity against resistant strains ( Fig. 2 D and E ), but the 2,6-NSCT Rituximab showed significant …
Tīmeklis2008. gada 25. janv. · Rituximab-mediated cytotoxicity in Raji clones. A, complement-mediated cytototoxicity. Parental, CD52 low, and CD52 high Raji cell clones were incubated with 10 μg/mL of rituximab or trastuzumab in the presence of 30% of either active or heat-inactivated human serum as a source of complement.
Tīmeklis2010. gada 6. maijs · It was recently demonstrated that incubation of CD20 + B-cell tumors with rituximab leads to decreased surface levels of CD20 accompanied by induction of several components of the ubiquitin-proteasome system. 31 Therefore, Raji cells were incubated with 10 μg/mL rituximab for 24 to 72 hours to determine …
Tīmeklis2024. gada 18. dec. · We developed Raji and Ramos cells that were resistant to rituximab-mediated CDC as previously described 32. Briefly, the original Raji or Ramos cells were treated with escalating rituximab (Roche ... laporan bergambar pintar botaniTīmeklisRaji xenograft model. Raji cells are a human B lymphocyte cell line that was established from the blood of a patient with Burkitt lymphoma in 1963. Burkitt lymphoma is a type … laporan bergambar lawatanTīmeklisIn this article we describe the efficacy of 131 I-rituximab in CD20-expressing Raji cells. Rituximab labeled with 131 I was purified on a PD-10 column and characterized … laporan berkelanjutan bankTīmeklisNanoprobe-treated Raji cells also showed the most drastic decrease in mitochondrial membrane potential and Bcl-2 expression, compared to rituximab and … laporan berkelanjutan antamTīmeklis2009. gada 3. dec. · Rituximab-resistant cell lines (Raji-R and Daudi-R) were generated from Raji and Daudi cells as described previously. 23, 24 Eight-week-old female BALB/c SCID mice were housed in pathogen-free conditions and were treated in accordance with guidelines of the Committee on Animals of the Second Military Medical … laporan bergambar kecacatanTīmeklis2014. gada 10. janv. · In a co-incubation model, Raji cells were incubated for 4 h with NK cells in presence of 100 μg/ml rituximab, GolgiStop, anti-CD107a antibody and 1 μ M R406, ibrutinib or CAL-101. Before ... laporan beritaTīmeklisRituxan/Mabthera (rituximab) is a chimeric human/murine monoclonal antibody targeting the CD20 antigen expressed on the surface of B cells. Rituxan is used therapeutically in the treatment of hematological cancers and autoimmune disorders. A number of Rituxan biosimilars have been launched across the world, signifying the … laporan berkala adalah